Values First Advisors Inc. Has $762,000 Holdings in Shockwave Medical, Inc. (NASDAQ:SWAV)

Values First Advisors Inc. boosted its position in Shockwave Medical, Inc. (NASDAQ:SWAV) by 27.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,000 shares of the company’s stock after buying an additional 859 shares during the period. Values First Advisors Inc.’s holdings in Shockwave Medical were worth $762,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Norges Bank bought a new position in Shockwave Medical during the fourth quarter worth $104,982,000. JPMorgan Chase & Co. grew its stake in Shockwave Medical by 57.9% in the first quarter. JPMorgan Chase & Co. now owns 1,273,747 shares of the company’s stock valued at $276,185,000 after acquiring an additional 467,237 shares during the period. Wellington Management Group LLP increased its stake in Shockwave Medical by 33.5% during the 3rd quarter. Wellington Management Group LLP now owns 1,805,771 shares of the company’s stock valued at $359,529,000 after purchasing an additional 453,048 shares in the last quarter. State Street Corp increased its position in shares of Shockwave Medical by 56.5% during the second quarter. State Street Corp now owns 1,125,735 shares of the company’s stock worth $215,207,000 after acquiring an additional 406,327 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in Shockwave Medical by 37.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,394,767 shares of the company’s stock valued at $302,428,000 after purchasing an additional 382,374 shares during the last quarter. Institutional investors own 95.35% of the company’s stock.

Shockwave Medical Stock Performance

Shares of SWAV traded up $3.02 during trading hours on Friday, hitting $325.63. The company’s stock had a trading volume of 814,504 shares, compared to its average volume of 698,070. The company has a market cap of $12.18 billion, a price-to-earnings ratio of 84.14, a PEG ratio of 2.73 and a beta of 0.90. The company has a debt-to-equity ratio of 1.09, a current ratio of 11.76 and a quick ratio of 10.73. The business has a 50 day simple moving average of $254.81 and a two-hundred day simple moving average of $215.40. Shockwave Medical, Inc. has a 52-week low of $157.00 and a 52-week high of $331.58.

Shockwave Medical (NASDAQ:SWAV) last issued its earnings results on Thursday, February 15th. The company reported $1.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.24. Shockwave Medical had a net margin of 20.17% and a return on equity of 23.97%. The business had revenue of $202.98 million for the quarter, compared to analysts’ expectations of $199.43 million. During the same quarter in the previous year, the firm posted $3.71 EPS. The business’s revenue for the quarter was up 41.0% compared to the same quarter last year. On average, equities analysts expect that Shockwave Medical, Inc. will post 4.89 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Frank T. Watkins sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $198.99, for a total value of $397,980.00. Following the completion of the sale, the director now owns 4,532 shares in the company, valued at approximately $901,822.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Shockwave Medical news, Director Frank T. Watkins sold 2,000 shares of the company’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $198.99, for a total value of $397,980.00. Following the completion of the transaction, the director now directly owns 4,532 shares in the company, valued at approximately $901,822.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Trinh Phung sold 1,287 shares of Shockwave Medical stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $232.18, for a total value of $298,815.66. Following the sale, the vice president now owns 32,933 shares in the company, valued at $7,646,383.94. The disclosure for this sale can be found here. Insiders have sold 115,813 shares of company stock worth $28,337,059 in the last ninety days. 3.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on SWAV shares. Morgan Stanley cut their target price on Shockwave Medical from $284.00 to $223.00 and set an “overweight” rating on the stock in a research report on Monday, December 4th. CL King initiated coverage on shares of Shockwave Medical in a report on Wednesday. They issued a “buy” rating and a $368.00 target price for the company. TheStreet upgraded shares of Shockwave Medical from a “c+” rating to a “b” rating in a report on Thursday, February 15th. Needham & Company LLC boosted their target price on Shockwave Medical from $260.00 to $286.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. Finally, Piper Sandler lifted their price target on Shockwave Medical from $275.00 to $290.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $271.44.

About Shockwave Medical

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.